预测胰腺导管腺癌新辅助治疗反应的常用生物标志物

Common biomarkers used to predict response to neoadjuvant therapy in pancreatic ductal adenocarcinoma

胰腺导管腺癌(PDAC)恶性程度高,预后差,发病率逐年升高。PDAC的治疗方式不仅取决于诊断时的疾病分期,还与复杂的解剖关系密不可分。近年来,对于技术上可切除的病变的首选治疗方法已经从先行手术逐渐转向了新辅助治疗。选择合适的方案并判断治疗反应对于最佳的肿瘤学结果至关重要,尤其是在这种情况下传统影像学方法已被证明并不可靠。肿瘤生物标志物作为辅助实验室检查,有可能在治疗计划选择、治疗监测中发挥关键作用。该文将介绍目前常用的PDAC生物标志物,并讨论这些标志物在新辅助治疗中可能的应用价值,并确定将其用作治疗方案选择、评估治疗进展、预后或潜在复发的标志物的能力。

Pancreatic ductal adenocarcinoma(PDAC)has a high degree of malignancy and a poor prognosis,with its morbidity increasing year by year.The treatment of PDAC depends not only on the disease staging at the time of diagnosis,but also on the complex anatomical relationships.In recent years,the preferred treatment for technically resectable lesions has gradually shifted from upfront surgery to neoadjuvant therapy.Choosing appropriate regimens and evaluating the treatment responses are critical for the best oncology outcome,especially in cases where conventional imaging methods have been proven to be unreliable.As auxiliary laboratory examination,tumor biomarkers may play a key role in treatment regimen selection and treatment monitoring.This paper will introduce the current commonly used PDAC biomarkers and discuss their potential value of applications in neoadjuvant therapy,and determine their ability to be used as treatment regimen selection,and the biomarkers to evaluate treatment progress,prognosis or potential recurrence.